The field of T cell immunotherapy has moved from theory to cure with remarkable clinical responses against hematologic malignancies achieved with CART cells. At present, these therapies rely on autologous T cells harvested from the peripheral blood and genetically engineered with each patient dose. Dr Crooks will present data on a new method that allows engineered T cells to be generated in vitro from hematopoietic and pluripotent stem cells, providing an experimental model of human and murine thymopoiesis, as well as a potential off-the-shelf approach for T cell immunotherapy.